VTD (velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma.

被引：0
|
作者：
Alexaman, R [1 ]
Wang, LM [1 ]
Weber, DM [1 ]
Delasalle, KB [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
210
引用
收藏
页码：64A / 64A
页数：1
相关论文
共 50 条
  • [41] Cytogenetics in newly diagnosed multiple myeloma.
    Testoni, N
    Ruggeri, D
    Tosi, P
    Carboni, C
    Iacurti, E
    Martinelli, G
    Ronconi, S
    Cavo, M
    Tura, S
    BLOOD, 1999, 94 (10) : 306B - 306B
  • [42] Thalidomide and dexamethasone for newly diagnosed multiple myeloma: Is this really the standard of care? Reply
    Anderson, Kenneth C.
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2968 - 2969
  • [43] Comparison of VTD (velcade-thalidomide-dexamethasone) and a conventional chemotherapy induction regimen: effect on stem cell mobilization and engraftment of ASCT (autologous stem cell transplantation) for newly diagnosed multiple myeloma
    Requena, M. J.
    Yebra, E.
    Berberana, M.
    Payamps, C.
    Diaz Goizueta, M.
    Riaza, R.
    Penalver, M. A.
    Rodriguez, R.
    Sanchez Godoy, P.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S212 - S213
  • [44] Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation.
    Garderet, Laurent
    Iacobelli, Simona
    Moreau, Philippe
    Dib, Mamoun
    Caillot, Denis
    Niederwieser, Dietger W.
    Masszi, Tamas
    Fontan, Jean
    Michallet, Mauricette
    Gratwohl, Alois
    Milone, Giuseppe
    Doyen, Chantal
    Pegourie, Brigitte
    Hajek, Roman
    Casassus, Philippe
    Kolb, Brigitte
    Chaleteix, Carine
    Hertenstein, Bernd
    Onida, Francesco
    Ludwig, Heinz
    Vekemans, Marie Christiane
    Ketterer, Nicolas
    Daguenel, Anne
    Gorin, Norbert C.
    Harousseau, Jean Luc
    de Witte, Theo
    Morris, Curly
    Gahrton, Gosta
    BLOOD, 2010, 116 (21) : 1254 - 1254
  • [45] Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
    Sonneveld, Pieter
    Asselbergs, Emilie
    Zweegman, Sonja
    van der Holt, Bronno
    Kersten, Marie Jose
    Vellenga, Edo
    van Marwijk-Kooy, Marinus
    Broyl, Annemiek
    de Weerdt, Okke
    Lonergan, Sarah
    Palumbo, Antonio
    Lokhorstl, Henk
    BLOOD, 2015, 125 (03) : 449 - 456
  • [46] Thalidomide/Dexamethasone Induction Therapy in Newly Diagnosed Myeloma Patients with Renal Failure
    Tosi, P.
    Tacchetti, P.
    Zamagni, E.
    Tacchetti, P.
    Ceccolini, M.
    Perrone, G.
    Brioli, A.
    Pallotti, M. C.
    Petrucci, A.
    Baccarani, M.
    Cavo, M.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S30 - S30
  • [47] Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma
    Xu, Peipei
    Zhou, Rongfu
    Xu, Jingyan
    Ouyang, Jian
    Shao, Xiaoyan
    Chen, Bing
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (05) : 2099 - 2106
  • [48] Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma
    Shen, Yunfeng
    Zhou, Xin
    Wang, Zhi
    Yang, Guohua
    Jiang, Yuanqiang
    Sun, Chao
    Wang, Jing
    Tong, Yi
    Guo, Hongfeng
    LEUKEMIA RESEARCH, 2011, 35 (02) : 147 - 151
  • [49] VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma
    M Pineda-Roman
    M Zangari
    F van Rhee
    E Anaissie
    J Szymonifka
    A Hoering
    N Petty
    J Crowley
    J Shaughnessy
    J Epstein
    B Barlogie
    Leukemia, 2008, 22 : 1419 - 1427
  • [50] Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
    Rajkumar, SV
    Hayman, S
    Lacy, MQ
    Dispenzieri, A
    Geyer, SM
    Kabat, B
    Zeldenrust, SR
    Kumar, S
    Greipp, PR
    Fonseca, R
    Lust, JA
    Russell, SJ
    Kyle, RA
    Witzig, TE
    Gertz, MA
    BLOOD, 2005, 106 (11) : 230A - 231A
12345